| 2010 |
|
- Cosmo Pharmaceuticals announces preliminary interim result of
its tender offer for BioXell
|
| 2009 |
|
- Cosmo's CB-03-01 phase II pilot study in acne demonstrates
superiority over Retin A® on 11 December
- Cosmo publishes the public tender offer to acquire BioXell
on 8 December
- Cosmo offers to acquire BioXell on 18
November
|
| 2008 |
|
- Strategic collaboration with Santarus for U.S rights to
Budesonide MMX® and Rifamycin MMX® on 15 December
- Licensing agreement with Dr. Falk for Rifamycin
SV MMX®
- Cosmo awarded US patent for use of its MMX®
technology
|
| 2007 |
|
- UK Market launch of Mezavant XL® by Shire plc on 05
November.
- Licensing agreement with Ferring for Budesonide MMX™
- US Market launch of Lialda® by Shire plc on 19 March.
- IPO on the Swiss Stock Exchange (SWX) on 12
March.
|
| 2006 |
|
- FDA approval for the manufacturing of tablets to the USA.
- Completion of 2.000 sq m plant in Lainate,
Milan.
|
| 2005 |
|
- Completion of first financing round of €20.4 million by
Cosmo Holding S.p.A.
- Lialda®/Mezavant® Supply Agreement with Shire
plc.
|
| 2004 |
|
- Opening of an R&D laboratory in Catania,
Italy.
|
| 2001 |
|
- Lialda®/Mezavant® globally out-licensed to Giuliani
S.p.A./ Shire plc*.
|
| 1999 |
|
- Filing of the first MMX® Multi Matrix technology patent for
the controlled release of tablets in the gastro-intestinal
tract.
|
| 1998 |
|
- Strategic decision to develop novel oral formulations of
off-patent drugs to generate new patentable
applications.
|
| 1997 |
|
- Foundation of Cosmo S.p.A. by purchasing contract manufacturing
unit in Lainate (Milan) from Parke Davis (now Pfizer
Group).
|
